+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of a drug called BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 trial compares three different doses of the drug administered orally against a placebo. The study focuses on participants aged 18 to 70 who have a confirmed diagnosis of multiple sclerosis with spasticity lasting at least 6 months. Participants are randomly assigned to one of four groups three groups receive different doses of BMS-986368, and one group receives a placebo. The drug is given on specified days, though exact dosing schedules are not detailed in the summary. The study is double-blind, meaning neither participants nor most study staff know who receives the active drug or placebo. This treatment phase is planned to last at least 6 weeks, during which various assessments will take place. During the study, participants undergo evaluations including the Modified Ashworth Scale for spasticity, Numeric Rating Scale for spasticity severity, Timed 25-Foot Walk, and other clinical assessments. Blood samples will be collected to measure plasma levels of BMS-986368. Safety is closely monitored up to 16 weeks, including adverse events and withdrawal symptoms. The main outcome measure tracks changes in spasticity score at 6 weeks. Participants progress will be assessed through scheduled visits, and the total participation duration may extend beyond the treatment period for safety follow-up.

Age: 18Years - 70YearsAll GendersPhase 2
61 locations